RT Journal Article
T1 Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
A1 Gounder, Mrinal
A1 Abdul Razak, Albiruni R
A1 Gilligan, Adrienne M
A1 Leong, Hoyee
A1 Ma, Xiwen
A1 Somaiah, Neeta
A1 Chawla, Sant P
A1 Martin-Broto, Javier
A1 Grignani, Giovanni
A1 Schuetze, Scott M
A1 Vincenzi, Bruno
A1 Wagner, Andrew J
A1 Chmielowski, Bartosz
A1 Jones, Robin L
A1 Shah, Jatin
A1 Shacham, Sharon
A1 Kauffman, Michael
A1 Riedel, Richard F
A1 Attia, Steven
K1 advanced liposarcoma
K1 pain
K1 patient-reported outcomes
K1 progression-free survival
K1 quality of life
K1 selective inhibitor of nuclear export
K1 selinexor
AB Objective: Compare health-related quality of life (HRQoL) of selinexor versus placebo in patients with dedifferentiated liposarcoma. Materials & methods: HRQoL was assessed at baseline and day 1 of each cycle using the European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire. Results were reported from baseline to day 169 (where exposure to treatment was maximized while maintaining adequate sample size). Results: Pain scores worsened for placebo versus selinexor across all postbaseline visits, although differences in HRQoL at some visits were not significant. Other domains did not exhibit significant differences between arms; however, scores in both arms deteriorated over time. Conclusion: Patients treated with selinexor reported lower rates and slower worsening of pain compared with patients who received placebo.
YR 2021
FD 2021-04-15
LK http://hdl.handle.net/10668/17582
UL http://hdl.handle.net/10668/17582
LA en
DS RISalud
RD Apr 7, 2025